NCT03993873 2025-10-01SHIELD-1Turning Point Therapeutics, Inc.Phase 1 Active not recruiting95 enrolled
NCT04248829 2024-12-03Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)Yuhan CorporationPhase 3 Active not recruiting393 enrolled 13 charts